EPA Ethyl Ester Reduces Apolipoprotein C-III and Triglycerides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly those related to high triglycerides and cholesterol levels, often fail to adequately lower triglycerides while maintaining LDL-C levels, and may include side effects or inadequate responses in patients on statin therapy.
Innovation Solution
Administering a pharmaceutical composition comprising eicosapentaenoic acid (EPA) or its derivatives, specifically ethyl eicosapentaenoate, in doses of 1-4 grams daily, which reduces apolipoprotein C-III levels and effectively lowers triglycerides without significantly increasing LDL-C levels, even in patients on stable statin therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments for cardiovascular diseases are used, then LDL-C levels are managed, but triglyceride levels are not adequately lowered
Solution Approach 1:
The patent changes the chemical parameter by using pure eicosapentaenoic acid (EPA) ethyl ester with at least 95% purity, specifically dosing at 2-4 grams per day. This high-dose pure EPA formulation fundamentally alters the treatment approach compared to conventional mixed fish oils or statin therapy alone, achieving significant triglyceride reduction (30-60% or greater) while maintaining LDL-C control.
2Quantity of substance
If statin therapy is used to manage cholesterol, then LDL-C levels are reduced, but triglyceride reduction is inadequate and side effects occur
Solution Approach 1:
The patent introduces pure EPA ethyl ester as an intermediary substance that works synergistically with or independently from statin therapy. The EPA ethyl ester serves as a mediator that specifically targets triglyceride reduction through multiple mechanisms including inhibition of hepatic triglyceride synthesis and enhancement of lipoprotein lipase activity, thereby reducing triglycerides without the harmful side effects associated with high-dose statins.
3Quantity of substance
If high doses of EPA are administered, then triglyceride and apolipoprotein C-III levels are significantly reduced, but the composition complexity increases
Solution Approach 1:
The patent extracts and isolates pure eicosapentaenoic acid ethyl ester from complex fish oil sources, achieving at least 95% purity. This extraction process removes all unwanted substances, contaminants, and variable components found in natural fish oils, resulting in a standardized, controlled composition that simplifies dosing and eliminates the complexity of managing mixed fatty acid profiles while maintaining potent triglyceride and apoC-III reduction effects.
Data Source
AI summary
In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.